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Weexplored the effects of valproate treatment on visual cortex excitability changes inmigrainewith aura
patients. Abnormal cortical excitability has been suggested to play an important role in the etiopatho-
genesis of migraine; in particular, it has been suggested a failure of inhibitory circuits in migraine with
aura. Valproate acts as a central GABA agonist and it is reasonable suppose that VPA couldmodify cortical
excitability state. Phosphene threshold (PT) was assessed at baseline and after 1Hz rTMS before and after
one month therapy. We found that low-frequency rTMS in drug-free migraineurs decreased PT, while
the treatment with the GABA agonist valproate is able to revert the effect of 1Hz rTMS over the occipital
cortex. If the paradoxical increasing of PT to 1Hz rTMS is consequent upon the deficiency of intracortical
inhibitory circuits in migraine, it seems reasonable to suppose that the effect of valproate is due to a
recovery of activity of these circuits.
© 2009 Elsevier Ireland Ltd. All rights reserved.
Abnormal cortical excitability has been suggested to play an impor-
tant role in the etiopathogenesis of migraine. The relevance of
neuronal excitability recently received further support by the find-
ing that patients affected by familial hemiplegic migraine (FHM)
show abnormalities of P/Q calcium channels in FHM type 1 [28],
dysfunction of Na/K pump, as evidenced in FHM type 2 [12] or dys-
function of the neuronal sodiumchannel SCN1A in FHM type 3 [14].
FHM and commonmultifactorial migraine have many overlapping
clinical features indicating that they likely share underlying patho-
physiological pathways, even if the question about relationship
between FHM and typical migraine is still debated.
Excitability of visual cortex can be assessed by delivering tran-
scranial magnetic stimulation (TMS) over the occipital cortex to
induce perception of phosphenes.
The lowest intensity of magnetic pulses needed to induce
phosphene’s perception is known as phosphene threshold (PT).
Repetitive transcranial magnetic stimulation (rTMS) is a tool to
modulate cortical excitability [30,31]; in particular low-frequency
is known to decrease excitability of visual cortex in healthy
subjects, increasing PT [6,7]. In contrast with these findings, low-
frequency rTMSwhen applied on the occipital cortex ofmigraineur
with aura patients was found to exert a facilitatory effect, decreas-
ing PT [7].
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The authors interpreted these results as consequent upon a
failure of inhibitory circuits in migraine with aura, unable to be
upregulated by low-frequency rTMS.
These results on the visual cortices are in agreement with find-
ings coming by psychophysical studies showing that migraineurs
present disturbance in visual task that are critically dependent
upon integrity of GABA-mediated inhibitory circuits. Evidence in
support of reduced inhibition in migraineurs was also provided by
Mulleners et al. [26] through a TMS paradigm of visual interference
[1]. These authors indeed showed that magnetic pulses delivered
on visual cortex 80–120ms after visual stimulation induced less
interference of visual perception in migraineurs than in controls.
Sodium valproate is an antiepileptic drug that acts as central
GABA agonist and is also effective in the preventive treatment of
migraine [16,15]. A further study by Mulleners et al. [27] showed
that two-month treatment with valproate in migraine patients
determined a significant increase in phosphene threshold (PT) val-
ues correlated with amelioration of migraine.
On such grounds we were interested to explore if treatment
withvalproate inmigrainewith aurapatients couldhelp recovering
the efficiency of cortical inhibitory circuits in the visual cortex. We
expected that valproate therapy could revert the paradoxical facil-
itatory pattern of PT by 1Hz rTMS on visual cortex of migraineurs.
Nine patients (2M/7F, age: 39±12 years, range: 22–58) affected
by migraine with aura participated into the study. Patients were
consecutively recruited from the Headache Service of the Neu-
rology Department at University of Palermo, Italy; diagnosis of
migraine with typical aura was made on the basis of clinical
0304-3940/$ – see front matter © 2009 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.neulet.2009.09.054
A. Palermo et al. / Neuroscience Letters 467 (2009) 26–29 27
Fig. 1. Study design.
interview using the diagnostic criteria of the Headache Classifica-
tion by International Headache Society, 2004 (ICHDII code 1-2-1)
[20]. Patients were not taking any drug. All patients experienced
visual aura on at least 50% of their migraine attacks. Migraineurs
were examined interictally (at least 48h before or after an attack):
the absence of attack after the recording was checked by a tele-
phone call. To avoid unspecific effects on cortical excitability [34],
female subjects were not tested during the menstrual phase. All
patients gave their informed consent and the studywas performed
according to the Declaration of Helsinki [32].
The design of the study is shown in Fig. 1. Patients were evalu-
ated three times: at the first visit they were given headache diaries
to rate headache frequency and severity according to the follow-
ing scale: 1: mild; 2: moderate and 3: severe. After one-month
follow-up they were re-examined and those with at least three
attacks per month were evaluated for phosphene induction. Those
who presented phosphenes (six patients: 1M/5F) underwent the
experimentalmagnetic stimulation paradigmand began treatment
with valproate that was chosen as GABA agonist drug. The drug was
titrated beginningwith a dosage of 200mg b.i.d. thatwas increased
of 200mg every three days until to reach the dosage of 500mgb.i.d.
Patients were requested to record every new symptom after the
starting of valproate therapy. One month after reaching full dose,
patients were re-examined with the same experimental paradigm
of magnetic stimulation.
The subjects were blindfolded and wore a tight fitting plastic
swimmer’s cap with a grid of 3×3 points (each point 2 cm apart)
centred over Oz. Magnetic stimuli were delivered by a Cadwell
high frequency magnetic stimulator equipped with a 9 cm water-
cooled figure of eight coil. The optimal point on the grid to induce
phosphenes was determined by a mapping procedure. Each ses-
sion started with the coil placed in the midline 2 cm above inion.
Afterwards, the coil was shifted laterally to both sides. To induce
phosphenes, pairs of magnetic stimuli with 50ms interstimulus
interval were used [6]. Magnetic stimulation began at intensity of
30% of maximal stimulator output and then was increased in steps
of 10% until phosphenes could be elicited in three of five trials or
until a maximum of 100% intensity of stimulation was reached.
Stimulation intensity lower than 100% was then fine-tuned to
determine the threshold at which phosphenes could just be visu-
Fig. 3. Mean PT values (± confidence intervals, 95%) before (—) and after (- - - ) one
month of valproate treatment, in baseline and post-1Hz rTMS.
alized. This intensity was defined as phosphene threshold (PT).
This procedure was performed before and after 1Hz rTMS given
for 15min at PT intensity over the optimal point for phosphene
induction.
Effects of valproate therapy on rTMS modulation of PT were
evaluated by means of ANOVA for repeated measures with Con-
dition (2 levels: pre- and post-rTMS) and Time (2 levels: before and
after treatment). Significance was set at p< .05.
rTMSwaswell tolerated and no side effectswere reported. Indi-
vidual values of PT in different conditions and time are shown in
Fig. 2.
The ANOVA showed significant main effects of Condition (F(1,
5) = 67,318, p< .001), of Time (F(1, 5) = 38,571, p< .002) and of the
interaction Condition×Time (F(1, 5) = 7737, p< .0005) (Fig. 3).
Duncan post-hoc analysis showed that PT significantly
decreased after rTMS indrug-freepatients (p<0.0005),while oppo-
site rTMS modulation was found after treatment with a significant
PT increasing (p<0.02). No significant differencewas found inbase-
line PT between conditions (before and after VPA treatment), even
if a slight trend in increasing was found after therapy (p=0.055).
The main result of our study was that the treatment with the
GABA agonist valproate is able in migraineurs with aura to revert
the effect of 1Hz rTMS over the occipital cortex. We found that
low-frequency rTMS in drug-free migraineurs decreased PT, while
an increasing in PT was observed in the same subjects after 30
days of valproate treatment. Our data before treatment replicated
those of previous reports [7] in migraineur with aura patients.
These findings were interpreted as due to a failure of inhibitory
circuits. In migraine, the loss of balance between facilitatory and
Fig. 2. Individual values of PT before and after one month of valproate treatment in baseline and after-1Hz rTMS.
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inhibitory circuits might invert the frequency-dependent effects
of rTMS on cortical excitability. A similar, abnormal modulatory
effect on PT was observed in migraine patients compared to con-
trols by using TDCs cathodal (inhibitory) stimulation [10]. These
results strengthened the notion of deficient inhibitory processes in
visual cortex of migraineurs, which were selectively revealed by
activity-modulating cortical input.
Several evidence in support of a reduced cortical inhibition in
migraine has been reported.
First Palmer et al. [29] andMulleners et al. [26] hypothesized the
deficiency of GABA-mediated circuits in visual cortex of migraine.
There is evidence from experiments in animal models that GABA-
ergic neurons are selectively damaged by a short period of hypoxia
[33], and that repeated episodes of cortical spreading depression
can cause selective suppression of GABA-ergic inhibitory function
[24]. The biological mechanisms responsible for reduced inhibition
in migraine are not definitively known, however, a hypofunction-
ality of Gi proteins in a group of subjects affected by migraine and
cluster headache has been hypothesized by Galeotti et al. [18].
Moreover, reduced GABA-B [3,11], and GABA-A [8] mediated
motor intracortical inhibitionhas been reported inmigraineurwith
aura patients.
These observations could account for the inefficient potentia-
tion of GABA-mediated circuits by low-frequency rTMS found in
migraine patients.
If the paradoxical increasing of PT to 1Hz rTMSwas consequent
upon the deficiency of intracortical inhibitory circuits in migraine,
the effect of valproate could be hypothesized as due to a recovery
of activity of these circuits.
Valproic acid (VPA) is a chemical compound that has found clin-
ical use as an anticonvulsant and mood-stabilizing drug, primarily
in the treatment of epilepsy, bipolar disorder, and less commonly
major depression. Valproate is believed to affect the function of the
neurotransmitter GABA (as a GABA transaminase inhibitor) in the
human brain [9,19,22]. In addition to blocking transamination of
GABA, valproate is believed to reverse the transamination process
to form more GABA. Hence, valproate indirectly acts as a central
GABA agonist. However, several other mechanisms of action have
beenproposed in recentyears, thatmakevalproic acidabroadspec-
trum drug, also used in migraine prophylaxis [15,4]. It is known
that cortical silent period (CSP) observable in the electromyogram
of the voluntarily contracted targetmusclewas prolonged by drugs
that influenceGABA-ergic inhibition in themotor cortex [36]. How-
ever, reports of VPA pharmacologic effects on the TMS-induced
CSP in healthy subjects [37,25] and in epileptic patients [23] are
contradictory.
These results suggested that VPA may have different modes
of action when given acutely to healthy subjects and when given
chronically to patients.
TMS has been extensively used to evaluate pharmacological
effects of VPA as antiepileptic drug, but there are no studies on
effects of valproate on cortical motor excitability in migraine with
aura patients.
Differently from Mulleners et al. [27], that found that two-
month treatment with valproate in migraineurs determined a
significant increase in phosphene threshold (PT), in our study, PT
showed only a trend to increase after the treatment, even if the
change did not reach the significance.
Methodological differences between studies: different period of
therapy anddifferent coil size used [27] aswell as the small number
of patients in our work could account for different results.
In conclusion, the opposite modulatory effects observed before
and after VPA treatment in migraine patients leave room for the
hypothesis that the different changes induced by low-frequency
rTMS could depend on the pre-existing state of excitatory and
inhibitory circuits in visual cortex [5,17]. On the basis of our data,
we cannot affirm that VPA treatment restored inhibition in our
patients, but it is reasonable suppose that VPA modified cortical
excitability state in order to normalize the modulatory response to
low-frequency rTMS. This appears also in agreement with recent
reports about the neurophysiological effects of other antiepilep-
tic drugs in migraine. Indeed, topiramate and levetiracetam were
foundable tonormalizedifferent aspects of cortical excitability that
have been found to be impaired in migraine [2,13,35].
The clinical efficacy of VPA is well known [21,16,15]. In the
present study we did not investigate this aspect that went beyond
the aim of the study because the short period of treatment and the
small number of patients.
Further studies in larger series of migraineur with aura patients
needed to support the hypothesis that the restoring of cortical inhi-
bition can be responsible of the clinical amelioration.
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